Similarly, DRP1-S616P is subject to pharmacologic control by targeted therapies against oncogenic MAPK signaling.<h4>Methods</h4>Building upon this foundation, we developed and characterized a recombinant murine monoclonal antibody (referred to as 3G11) with high specificity for human DRP1-S616P, raised against a peptide derived from the human DRP1 sequence.<h4>Results</h4>Using diverse experimental platforms, we demonstrate the robust utility of 3G11 to detect DRP1-S616P in melanoma cell extracts and isolated organelles. This evidence concerns the gene DNM1L and melanoma.